Illumina (NASDAQ:ILMN) Unveils New Sequencing Instrument, MiSeq

Goldman Sachs (NYSE:GS) says they're maintaining their rating on Illumina (NASDAQ:ILMN) after the unveiled a new sequencing instrument, MiSeq.

Also noted was the growing backlog of Illumina for its sequencing services, along with lower cost arrays.

Goldman raised their full year EPS estimates for 2011 through 2013 from 1.52, $1.92, and $2.31 to $1.48, $2.00, and $2.58.

They maintains their "Buy" rating on Illumina, which closed Wednesday at $66.95, down $0.39, or 0.58 percent. Goldman raised their price target on Illumina from $74 to $81.